A Non-randomized, Open, Dose Escalation Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LPM3480226 Tablets in Patients With Advanced Solid Tumors
This study is a non-randomized, open, multiple administration and dose escalation phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetic/pharmacodynamics Characteristics of multiple oral administration of LPM3480226 in patients with advanced solid tumors., determine its dose-limiting toxicity and maximum tolerated dose, and initially observe its clinical effectiveness, and explore the metabolites in plasma after administration.
100 Clinical Results associated with Nanjing Bonnuo Biotechnology Co., Ltd.
0 Patents (Medical) associated with Nanjing Bonnuo Biotechnology Co., Ltd.
100 Deals associated with Nanjing Bonnuo Biotechnology Co., Ltd.
100 Translational Medicine associated with Nanjing Bonnuo Biotechnology Co., Ltd.